Trexquant Investment LP Has $15.11 Million Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Trexquant Investment LP lessened its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 28.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 164,353 shares of the medical device company's stock after selling 65,236 shares during the quarter. Trexquant Investment LP owned 0.08% of Cooper Companies worth $15,109,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Cooper Companies during the 4th quarter valued at about $217,906,000. Raymond James Financial Inc. acquired a new position in Cooper Companies during the 4th quarter worth $64,826,000. Victory Capital Management Inc. increased its position in shares of Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company's stock worth $415,985,000 after purchasing an additional 574,899 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Cooper Companies by 13.2% in the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company's stock worth $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Finally, Wealthfront Advisers LLC increased its holdings in Cooper Companies by 4,594.1% in the fourth quarter. Wealthfront Advisers LLC now owns 569,812 shares of the medical device company's stock valued at $52,383,000 after buying an additional 557,673 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Stock Performance

COO traded down $4.40 during trading hours on Friday, hitting $73.77. The company's stock had a trading volume of 2,661,526 shares, compared to its average volume of 1,367,710. The Cooper Companies, Inc. has a fifty-two week low of $73.34 and a fifty-two week high of $112.38. The firm has a market capitalization of $14.75 billion, a PE ratio of 37.83, a PEG ratio of 2.25 and a beta of 1.01. The company has a 50-day simple moving average of $87.76 and a 200 day simple moving average of $96.24. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Remove Ads

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Piper Sandler reiterated an "overweight" rating and issued a $115.00 price target (down from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. StockNews.com cut shares of Cooper Companies from a "buy" rating to a "hold" rating in a report on Wednesday, December 11th. Robert W. Baird reduced their price target on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.